Interim guidance for clinicians considering the use of preexposure prophylaxis for the prevention of hiv infection in heterosexually active adults

Morbidity and Mortality Weekly Report

Volumn 61, Issue 31, 2012, Pages 586-589

  Smith, D K ^a   Thigpen, Michael C ^a   Nesheim, Steven R ^a   Lampe, Margaret A ^a   Paxton, Lynn A ^a   Samandari, Taraz ^a   Lansky, Amy ^a   Mermin, Jonathan ^a   Fenton, Kevin ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; ANTIRETROVIRUS AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; EMTRICITABINE; PHOSPHONIC ACID DERIVATIVE; TENOFOVIR;

ADULT; ARTICLE; DISEASE TRANSMISSION; DRUG CONTRAINDICATION; DRUG LABELING; FEMALE; HETEROSEXUALITY; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; PREGNANCY; PREGNANCY COMPLICATION; PUBLIC HEALTH SERVICE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK; SEXUAL BEHAVIOR; UNITED STATES;

ADENINE; ADMINISTRATION, ORAL; ADULT; ANTI-RETROVIRAL AGENTS; CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); DEOXYCYTIDINE; DRUG LABELING; FEMALE; HETEROSEXUALITY; HIV INFECTIONS; HOMOSEXUALITY; HUMANS; MALE; PHOSPHONIC ACIDS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; SEXUAL BEHAVIOR; UNITED STATES;

EID: 84864996766     PISSN: 01492195     EISSN: 1545861X     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Prejean J, Song R, Hernandez A, et al. Estimated HIV incidence in the United States, 2006-2009. PLoS One 2011;6:e17502.
2. CDC. Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men MMWR 2011;60:65-8.
3. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367:399-410.
4. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012;367:423-34.
5. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012;367:411-22.
6. Microbicide Trials Network. MTN statement on decision to discontinue use of oral tenofovir tablets in VOICE, a major HIV prevention study in women. Pittsburgh, PA: Microbicide Trials Network; 2011. Available at http://www.mtnstopshiv.org/node/3619. Accessed August 3, 2012.
7. Foster C, Lyall H, Olmscheid B, Pearce G, Zhang S, Gibb DM. Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine? HIV Med 2009;10:397-406.
8. Mugo NR, Heffron R, Donnell D, et al. Increased risk of HIV-1 transmission in pregnancy: a prospective study among African HIV-1-serodiscordant couples. AIDS 2011;25:1887-95.
9. Lampe MA, Smith DK, Anderson GJE, Edwards AE, Nesheim SR. Achieving safe conception in HIV-discordant couples: the potential role of oral preexposure prophylaxis (PrEP) in the United States. Am J Obstet Gynecol 2011;204:488.
10. Panel on treatment of HIV-infected pregnant women and prevention of perinatal transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. 2012. Available at http://aidsinfo.nih.gov/contentfiles/perinatalgl.pdf. Accessed August 3, 2012.
11. CDC. Characteristics associated with HIV infection among heterosexuals in urban areas with high AIDS prevalence-24 cities, United States, 2006-2007. MMWR 2011;60:1045-9.